Four out of five cancer therapies tested in phase III trials do not achieve clinically-meaningful benefit in prolonging survival

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.

July 26, 2024

Vol.50 No.30

By Jacquelyn Cobb and Paul Goldberg

News Analysis White House

Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025

What will happen to biomedical research and health care in the aftermath of the 2024 election? The differences in outcomes couldn’t be more stark.

July 26, 2024

Vol.50 No.30

By McKenzie Prillaman

Letter To The Editor

Tweaking the existing systems is not the answer to drug shortages

In the July 19 article “Platinum drugs are off the shortage list, but the underlying problem is unsolved,” FDA Commissioner Robert Califf and others describe a solution to the U.S. drug shortage as a matter of paying more for generic drugs.

July 26, 2024

Vol.50 No.30

Clinical Trials & Tribulations

Better oncology drug management could lead to improved outcomes, lower costs

Cancer treatment is steadily improving. The proof can be found in the number of patients with cancer living longer than ever before. Over the next decade, the number of people who have lived five or more years after their diagnosis is projected to increase approximately 30% to 16.3 million.

July 26, 2024

Vol.50 No.30

By Matt Ingram

In the Archives

When tobacco companies sponsored the Olympics

Tobacco companies have capitalized on the Olympics’ widespread cultural impact since the birth of the modern Olympic Games in 1896—until the practice was stopped in 1987.

July 26, 2024

Vol.50 No.30

In Brief

Jonathan Gerber named chief clinical officer of NYU Langone Health’s Perlmutter Cancer Center

Jonathan M. Gerber was named chief clinical officer of NYU Langone Health’s Perlmutter Cancer Center.

July 26, 2024

Vol.50 No.30

Four out of five cancer therapies tested in phase III trials do not achieve clinically-meaningful benefit in prolonging survival

YOU MAY BE INTERESTED IN

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025

Tweaking the existing systems is not the answer to drug shortages

Better oncology drug management could lead to improved outcomes, lower costs

When tobacco companies sponsored the Olympics

Jonathan Gerber named chief clinical officer of NYU Langone Health’s Perlmutter Cancer Center

Renew today!

Subscriber content

Login